|
Diabetes Technology & Therapeutics
IRIS II Study: Sensitivity and Specificity of Intact Proinsulin, Adiponectin, and the Proinsulin/Adiponectin Ratio as Markers for Insulin Resistance
To cite this article:
Matthias R. Langenfeld, Thomas Forst, Eberhard Standl, Hermann-Josef Strotmann, Georg Lübben, Sabine Pahler, Peter Kann, Andreas Pfützner.
Diabetes Technology & Therapeutics.
December 2004,
6(6): 836-843.
doi:10.1089/dia.2004.6.836.
Matthias R. Langenfeld, M.D.IKFE Institute for Clinical Research and Development, Mainz, Germany. Thomas Forst, M.D.IKFE Institute for Clinical Research and Development, Mainz, Germany. Eberhard Standl, M.D.University Hospital München-Schwabing, München, Germany. Hermann-Josef Strotmann, M.D.IKFE Institute for Clinical Research and Development Rotenburg, Rotenburg, Germany. Georg Lübben, M.D.Medical Department, Takeda Pharma, Aachen, Germany. Sabine Pahler, M.Sc.IKFE Institute for Clinical Research and Development, Mainz, Germany. Peter Kann, M.D.University Hospital Marburg, Marburg, Germany. Dr. Andreas Pfützner, M.D., Ph.D.IKFE Institute for Clinical Research and Development, Mainz, Germany. University of Applied Sciences, Rheinbach, Germany. Objective: This study was performed to compare the specificity and sensitivity of intact proinsulin, adiponectin, and their ratio (proinsulin/adiponectin) in the prediction of insulin resistance as assessed by the homeostasis model assessment (HOMA) score (≥2 = resistant). Research Design and Methods: Using a cross-sectional approach, 500 orally treated patients with type 2 diabetes (272 women, 238 men; mean ± SD age, 64.8 ± 11.6 years; hemoglobin A1c, 7.0 ± 1.5%; disease duration, 5.8 ± 6.1 years) were investigated. Various cutoffs for body mass index-adjusted adiponectin and proinsulin/adiponectin were compared with the established cutoff value of 10 pmol/L for fasting proinsulin. Results: Fasting proinsulin correlated more closely with the HOMA score (r = 0.560, P < 0.001) than fasting adiponectin (r = -0.204, P < 0.001) or proinsulin/adiponectin (r = 0.355, P < 0.001). For proinsulin, specificity and sensitivity for insulin resistance in correlation to the HOMA score results were 96% and 70%, respectively. At a comparable specificity level to proinsulin, adiponectin did not reach a comparable sensitivity (14%), while the proinsulin/adiponectin ratio almost reached the same sensitivity (65%). Overall, patients with elevated proinsulin had a higher prevalence of micro- and macrovascular disease [odds ratio 1.47 (adiponectin, 1.08; proinsulin/ adiponectin, 1.48) and 1.34 (adiponectin, 1.32; proinsulin/adiponectin, 1.27), respectively]. Conclusions: Elevation of fasting intact proinsulin seems to be the more specific marker for insulin resistance and increased cardiovascular risk than suppression of fasting adiponectin. Formation of the ratio does not lead to a further increase in the predictive value.  This paper was cited by:Fixed-dose combination of pioglitazone and glimepiride in the treatment of Type 2 diabetes mellitus Thomas Forst, Andreas Pfützner Expert Review of Endocrinology & Metabolism. Jun 2007, Vol. 2, No. 3: 303-312 CrossRef Metabolic syndrome and mitochondrial function: Molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function Garth L. Nicolson Journal of Cellular Biochemistry. May 2007, Vol. 100, No. 6: 1352-1369 CrossRef
|
|